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To the Editor:
In May 2012, Yatabe et al.1,2 
encouraged the medical community 
to report therapeutic experiences with 
unusual EGFR mutations and the results 
of the therapeutic experiences associ-
ated. In this brief communication, we 
would like to describe our experience 
with a patient harboring such mutation.
In March 2012, a 58-year-old 
white man was referred to our hospital 
with a cT4N1M1b (stage IV) adenocar-
cinoma of the right lung diagnosed 3 
years ago, because of a persistent dry 
cough. He had multiple nodules and 
masses in the right lung, the greatest 
measuring 3.3 cm, with an ipsilateral 
metastatic paratracheal lymphnode, and 
metastatic bone lesions. He presented 
with a Zubrod (Eastern Cooperative 
Oncology Group) performance sta-
tus of 0 and had never smoked. He 
was initially treated with carboplatin, 
pemetrexed, and bevacizumab each 3 
weeks for four cycles, with good toler-
ance and a partial response.
At the time of the cytotoxic treat-
ment conclusion, EGFR testing became 
available, and in January 2010, the 
patient tested positive for an exon 18 
mutation, G719D (Fig. 1). At that time, 
maintenance therapy was initiated with 
Erlotinib 150 mg once daily, reduced 
to 100 mg once daily 1 month later 
because of skin rash grade 3 (Common 
Terminology Criteria for Adverse 
Events, version 3). He presented par-
tial response after 1 month of treat-
ment. Erlotinib 100 mg was maintained 
for 24 months, with further objective 
response followed by sustained sta-
ble disease, until bone progression in 
February 2012.
Considering the patient’s response 
to EGFR tyrosine kinase inhibitor, we 
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FIGURE 1.  Genetic sequencing by 
the Sanger method (image courtesy of 
Prof. Mariano Zalis).
decided to increase Erlotinib dose to 
150 mg once daily, which the patient 
maintained for 4 months, with no fur-
ther disease progression, sustaining a 
Zubrod performance status of 0.
Although EGFR exon 18 muta-
tions are associated with sensitivity to 
first-generation EGFR TKIs,3 they are 
rare; in most published series, its preva-
lence ranges from 1% to 4% of patients 
with EGFR mutations, being also a 
possible target for the novel TKI nera-
tinib.4 The mutation found most often is 
described as the G719X mutation, as in 
the case briefly depicted. In this case, 
we observed good clinical response in 
this unusual setting.
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